Avidity Biosciences’ treatment of facioscapulohumeral muscular dystrophy, or FSHD, was granted orphan designation by the FDA, according to a post to the agency’s website. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RNA: